- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-NOTC4/ NOTCH4/ INT3 monoclonal antibody
Anti-NOTC4/ NOTCH4/ INT3 antibody for FACS & in-vivo assay
Go to NOTCH4/NOTCH4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T49453-Ab-1/ GM-Tg-hg-T49453-Ab-2 | Anti-Human NOTCH4 monoclonal antibody | Human |
| GM-Tg-rg-T49453-Ab-1/ GM-Tg-rg-T49453-Ab-2 | Anti-Rat NOTCH4 monoclonal antibody | Rat |
| GM-Tg-mg-T49453-Ab-1/ GM-Tg-mg-T49453-Ab-2 | Anti-Mouse NOTCH4 monoclonal antibody | Mouse |
| GM-Tg-cynog-T49453-Ab-1/ GM-Tg-cynog-T49453-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NOTCH4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T49453-Ab-1/ GM-Tg-felg-T49453-Ab-2 | Anti-Feline NOTCH4 monoclonal antibody | Feline |
| GM-Tg-cang-T49453-Ab-1/ GM-Tg-cang-T49453-Ab-2 | Anti-Canine NOTCH4 monoclonal antibody | Canine |
| GM-Tg-bovg-T49453-Ab-1/ GM-Tg-bovg-T49453-Ab-2 | Anti-Bovine NOTCH4 monoclonal antibody | Bovine |
| GM-Tg-equg-T49453-Ab-1/ GM-Tg-equg-T49453-Ab-2 | Anti-Equine NOTCH4 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T49453-Ab-1/ GM-Tg-hg-T49453-Ab-2; GM-Tg-rg-T49453-Ab-1/ GM-Tg-rg-T49453-Ab-2; GM-Tg-mg-T49453-Ab-1/ GM-Tg-mg-T49453-Ab-2; GM-Tg-cynog-T49453-Ab-1/ GM-Tg-cynog-T49453-Ab-2; GM-Tg-felg-T49453-Ab-1/ GM-Tg-felg-T49453-Ab-2; GM-Tg-cang-T49453-Ab-1/ GM-Tg-cang-T49453-Ab-2; GM-Tg-bovg-T49453-Ab-1/ GM-Tg-bovg-T49453-Ab-2; GM-Tg-equg-T49453-Ab-1/ GM-Tg-equg-T49453-Ab-2 |
| Products Name | Anti-NOTCH4 monoclonal antibody |
| Format | mab |
| Target Name | NOTCH4 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-NOTCH4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species NOTC4/ NOTCH4/ INT3 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-T49453-Ag-1 | notch 4 (NOTCH4) protein |
Target information
| Target ID | GM-T49453 |
| Target Name | NOTCH4 |
| Gene ID | 4855,18132,406162,717323,481726,101080381,536128,100059541 |
| Gene Symbol and Synonyms | Int-3,INT3,N4,NOTCH4 |
| Uniprot Accession | Q99466 |
| Uniprot Entry Name | NOTC4_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Cytokine Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000204301 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: NOTCH4, gene name: NOTCH4, also named as INT3. This gene encodes a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types. Notch signaling is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells through binding of Notch family receptors to their cognate ligands. The encoded preproprotein is proteolytically processed in the trans-Golgi network to generate two polypeptide chains that heterodimerize to form the mature cell-surface receptor. This receptor may play a role in vascular, renal and hepatic development. Mutations in this gene may be associated with schizophrenia. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
